Vaishali Sanchorawala

Professor

General field of research:

Plasma cell dyscrasia, Amyloidosis

Contact information:

Office

820 Harrison Avenue, FGH 1007

Boston, MA 02118

Phone: (617)-638-7002

Fax: (617)-414-1831

Email: vaishali.sanchorawala@bmc.org

 Other research websites:

http://www.bu.edu/amyloid

 Keywords:

Plasma cell dyscrasia, High-dose chemotherapy and autologous stem cell transplantation, AL amyloidosis, Multiple myeloma, Light chain deposition disease, Hematologic malignancies, Myeloma; Stem cell transplantation; Clinical trials

 Summary of research interest:

Dr. Vaishali Sanchorawala is the Director of the Autologous Stem Cell Transplantation Program at Boston University Medical Center. She has been affiliated with the Amyloid Treatment and Research Program of the Boston University School of Medicine since 1994. She has been one of the pioneers in the field of clinical research in AL amyloidosis.  Her work in the treatment of primary systemic amyloidosis has been published in many peer-reviewed journals, which has resulted in the evolution of the standard of care for these patients. She is currently heading several clinical trials in the treatment of AL amyloidosis, one of which is being conducted nationally through the Southwest Oncology Group.

Awards and Honors:

 2011          Research Mentoring Award nomination, Department of Medicine

2011         Compassionate Caregiver Award, Schwartz Center for Compassionate Healthcare

Recent publications:

  1. Salant DJ, Sanchorawala V, D’Agati VD.  2007.  CJASN Clinicopathologic Conference: A case of atypical light chain deposition disease — diagnosis and treatment. Clinical Journal of the American Society of Nephrology; 2(4):858-67.
  2. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.  2007.  Tandem cycles of high dose melphalan and autologous stem cell transplantation increased the response rate in AL amyloidosis. Bone Marrow Transplantation; 40:557-562.
  3. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC.  2007.  Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation. Blood; 110 (10):3561-3563.
  4. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM.  2008.  Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leukemia Lymphoma; 49(6):1108-15.
  5. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V.  2009.  Febrile reactions occurring with second cycle of high-dose melphalan and stem cell transplantation in patients with AL amyloidosis: A ‘Melphalan Recall’ reaction. Bone Marrow Transplantation; 15(2), 40.
  6. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. 2009.  Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica; 94(7): 1029–1032.
  7. Reece D, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand J, Vescio RA, Liu X, Elsayed YA, Cakana A, ComenzoRL.  2009.  Weekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose-esclation study. Blood; 114(8):1489-9.
  8. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, Quillen K, Sanchorawala V.  2009.  Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and stem cell transplantation: A case report with literature review. Amyloid, Journal of Protein Folding Disorders; 16(2): 103-107.
  9. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Annals of Hematology 2010; 89(6): 579-84. {Prepublished online on December 10, 2009}
  10. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and stem cell transplantation in patients with AL amyloidosis: A “Melphalan Recall” reaction. Bone Marrow Transplantation 2010; 45(1):21-4 {Prepublished online on May 4, 2009}
  11. Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB, Seldin DC.
  12. Durable hematologic complete responses can be achieved with Lenalidomide in AL amyloidosis. Blood 2010; 116(11): 1990-1.
  13. Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB, Sanchorawala V. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 2010; 116(23): 5071-2.
  14. Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V,  Skinner M, Madsen JC, Semigran MJ. Cardiac Transplantation Followed by Dose Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure. Transplantation 2010; 90(8): 905-11. {Prepublished online on August 20, 2010}
  15. Sanchorawala V, Seldin DC, Berk JL, Sloan JM, Doros G, Skinner M. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clinical Lymphoma, Myeloma & Leukemia 2010; 10(6): 469-472.
  16. Girnius S, Seldin DC, Quillen K, Dember LM, Segal A, Sanchorawala V. Long-term outcome of patients with monoclonal immunoglobulin deposition disease treated with high-dose melphalan and stem cell transplantation. Bone Marrow Transplantation 2011; 46: 161-162. {Prepublished online on April 12, 2010}
  17. Specter R, Sanchorawala V, Seldin DC, Shelton AC, Fennessey S, Finn KT, Zeldis JB, Dember LM. Kidney dysfunction during Lenalidomide treatment for AL amyloidosis. Nephrology Dialysis Transplantation 2011; 26(3): 881-886. {Prepublished online on August 5, 2010}
  18. Quillen K, Seldin DC, Finn KT, Sanchorawala V. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplantation 2011; 46: 976-980. {Prepublished online on October 18, 2010}
  19. Cowan AJ, Skinner M, Berk JL, Sloan JM, O’Hara C, Seldin DC, Sanchorawala V. Macroglossia – Not always AL amyloidosis. Amyloid 2011; 18(2): 83-86. {Prepublished online on March 14, 2011}
  20. Charlot M, Seldin DC, O’Hara C, Skinner M, Sanchorawala V. Localized amyloidosis of the breast: a case series. Amyloid 2011; 18(2): 72-75. {Prepublished online on April 18, 2011}
  21. Tsai SB, Seldin DC, Wu H, O’Hara C, Ruberg FL, Sanchorawala V. Myocardial infarction with “clean coronaries” caused by Amyloid light-chain AL amyloidosis: a case reposrt and literature review. Amyloid 2011 {Prepublished online on April 19, 2011}
  22. Reece D, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, Fermand J, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine D, van de Velde H, Cakana A, ComenzoRL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL-amyloidosis: results of a phase-1/2 study. Blood 2011 {Prepublished online on May 11, 2011}
  23. Seldin DC, Berk JL, Sam F, Sanchorawala V. Amyloidotic cardiomyopathy: Multidisciplinary approach to diagnosis and treatment. Heart failure clinics 2011; 7 (3): 385-393. {Prepublished online on May 20, 2011}
  24. Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL; For The Velcade Can2007 Study Group. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM. 2011 {Prepublished online on July 13, 2011}
  25. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346-4352. {Prepublished online on August 9, 2011}
  26. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica 2011; 96(12):1890-1892. {Prepublished online on August 22, 2011}
  27. Meier-Ewert HK, Sanchorawala V, Berk J, Finn KT, Skinner M, Seldin DC, Ruberg FL. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid 2011; 18 (1):125-126.
  28. Seldin DC, Andrea N, Berenbaum I, Berk JL, Connors L, Dember LM, Doros G, Fennessey S, Finn K, Girnius S, Lerner A, Libbey C, Meier-Ewert HK, O’Connell R, O’Hara C, Quillen K, Ruberg FL, Sam F, Segal A, Shelton A, Skinner M, Sloan JM, Wiesman JF, Sanchorawala V. High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid 2011;18 (1):122-124.
  29. Meier-Ewert HK, Sanchorawala V, Berk JL, Ruberg FL. Cardiac Amyloidosis: Evolving Approach to Diagnosis and Management. Current Treatment Options Cardiovascular Medicine 2011; 13: 528-542.
  30. Seldin DC, Sanchorawala V. Amyloidomics comes of age. Blood. 2012; 119(8):1795- 1796.
  31. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia. 2012; 26(11):2317-2325. {Prepublished online on April 5,  2012}
  32. Sanchorawala V, Seldin DC. AL amyloidosis: who, what, when, why, and where. Oncology (Williston Park). 2012; 26(2):164, 166, 169.
  33. Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res. 2012;2(1):9-17.
  34. Freeman B, Sloan JM, Seldin DC, Cowan AJ, Ruberg FL, Sanchorawala V. Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. Amyloid 2012; 19(3):156-160. {Prepublished online on June 11,  2012}
  35. Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, O’ Hara CJ, Doros G, Sanchorawala V. Amyloidosis of the gastrointestinal tract: a 13-year single center referral experience. Haematologica. 2013; 98(1):141-146. {Prepublished online on June 24,  2012}
  36. Tsai S, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, Doros G, Finn KT, Skinner M, Sanchorawala V. High-Dose Melphalan And Stem Cell Transplantation For Patients With AL Amyloidosis: Trends in Treatment-Related Mortality Over The Past 17 Years at a Single Referral Center. Blood 2012; 120(22): 4445-4446.
  37. Cowan AJ, Seldin DC, Skinner M, Quillen K, Doros G, Tan J, O’Hara C, Finn KT, Sanchorawala V. Amyloid Deposits in the Bone Marrow of Patients with AL Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment. Biol Blood Marrow Transplant. 2012; 18(12):1935-1938.{Prepublished online on July 26,  2012}
  38. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of AL amyloidosis: results of a phase II trial. Haematologica 2013; 98 (5):789-792. {Prepublished online on November 9, 2012}
  39. Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V. Microbiologically documented infections in patients undergoing high-dose melphalan and antilogous stem cell transplantation for the treatment of immunoglobulin light chain amyloidosis. Transplant Infectious Disease 2012; {Prepublished online on December 20, 2012}
  40. Sarosiek S, Seldin DC, Berk JL, Sanchorawala V. A Solitary Mediastinal Mass Due To Localized AL Amyloidosis: Case Report and Review of the Literature. Amyloid 2013 {Prepublished online on March 6,  2013}
  41. Girnius S, Seldin DC, Cibeira MT, Sanchorawala V. New Hematologic Response Criteria Predict Survival In AL Amyloidosis Patients Treated With High-Dose Melphalan And Autologous Stem Cell Transplantation. Journal of Clinical Oncology 2013 (accepted)
  42. Sanchorawala V, Shelton AC, Zeldis JB, Seldin DC. Risk of Second Primary Malignancy in Patients with AL amyloidosis Treated with Lenalidomide. American Journal of Hematology 2013 {Prepublished online on May 6,  2013}
  43. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Modified High-Dose Melphalan and Antilogous Stem Cell Transplantation for AL Amyloidosis or High-Risk Myeloma: Analysis of SWOG trial S0115. Bone Marrow Transplantation 2013 (accepted)
  44. Girnius S, Seldin DC, Meier-Ewert H, Sloan JM, Quillen K, Ruberg FL, Berk J, Doros G, Sanchorawala V. Safety and Efficacy of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients with AL Amyloidosis and Cardiac Involvement. Bone Marrow Transplantation 2013 {Prepublished online on December 9, 2013}
  45. von Keudell G, Sanchorawala V, O’Hara C, Seldin DC, Sloan JM. Simultaneous Presentation of Kappa-restricted Chronic Lymphocytic Leukemia and Lambda light chain AL Amyloidosis. Amyloid 2014 {Prepublished online on January 29, 2014}